CALISIANT - Trademark Details
Status: 731 - Second Extension - Granted
Image for trademark with serial number 88942439
Serial Number
88942439
Word Mark
CALISIANT
Status
731 - Second Extension - Granted
Status Date
2021-09-28
Filing Date
2020-06-01
Mark Drawing
4000 - Standard character mark Typeset
Published for Opposition Date
2020-08-11
Law Office Assigned Location Code
N10
Employee Name
FAIRBANKS, RONALD L
Statements
Goods and Services
Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2020-06-22
Primary Code
005
Current Trademark Owners
Party Type
20 - Owner at Publication
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Type
20 - Owner at Publication
Address
Please log in with your Justia account to see this address.
Party Type
10 - Original Applicant
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Allergan Sales, LLC
Address
Please log in with your Justia account to see this address.
Trademark Events
Event DateEvent Description
2020-06-04NEW APPLICATION ENTERED IN TRAM
2020-06-22NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2020-06-28ASSIGNED TO EXAMINER
2020-07-02APPROVED FOR PUB - PRINCIPAL REGISTER
2020-07-22NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2020-08-11PUBLISHED FOR OPPOSITION
2020-08-11OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2020-10-06NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2021-03-29TEAS EXTENSION RECEIVED
2021-03-29EXTENSION 1 FILED
2021-03-29EXTENSION 1 GRANTED
2021-03-31NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2021-09-28TEAS EXTENSION RECEIVED
2021-09-28EXTENSION 2 FILED
2021-09-28EXTENSION 2 GRANTED
2021-09-30NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED